The central nervous system tumor methylation classifier changes neuro-oncology practice for challenging brain tumor diagnoses and directly impacts patient care
Shirin Karimi(Princess Margaret Cancer Centre), Gelareh Zadeh(University Health Network), Yasin Mamatjan(Princess Margaret Cancer Centre), Suganth Suppiah(University of Toronto), Kenneth Aldape(National Institutes of Health), David G. Muñoz(St. Michael's Hospital), Phedias Diamandis(University Health Network), Farshad Nassiri(University Health Network), Sheila Mansouri(Princess Margaret Cancer Centre), Jeffrey Zuccato(University of Oklahoma Health Sciences Center)
Cited by 89
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
|Journal of Clinical Oncology|2013|1.1k
Challenges to curing primary brain tumours
|Nature Reviews Clinical Oncology|2019|965
Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy
|Acta Neuropathologica|2015|528